Search

Displaying results 9301 - 9310 of 10000 in total
  1. Drug

    Amfenac

    go.drugbank.com/drugs/DB15911
    Investigational

    Amfenac is an arylacetic acid derivative and a non0steroidal anti-inflammatory agent.[A275203, A275208]

  2. Drug

    ARCT-810

    go.drugbank.com/drugs/DB17683
    Investigational

    ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.

  3. Drug

    AMT-162

    go.drugbank.com/drugs/DB17922
    Investigational

    AMT-162 is an adeno-associated virus serotype rh10 encoding artificial anti-SOD1 miRNA.

  4. Drug

    AVID-200

    go.drugbank.com/drugs/DB18454
    Investigational

    AVID-200 is an Anti-transforming growth factor beta (TGF-β) trap fusion protein.

    Synonyms: Tgf-.beta. ligand trap comprised of tgf-.beta. receptor ectodomains fused to a human fc domain (avid-200)
  5. Drug

    Tildacerfont

    go.drugbank.com/drugs/DB18545
    Investigational

    Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring

    Synonyms: Pyrazolo(1,5-a)pyrimidine, 3-(4-chloro-2-(4-morpholinyl)-5-thiazolyl)-7-(1-ethylpropyl)-2,5-dimethyl-pyrazolo(1,3-a)pyrimidine, 3-(5-chloro-2-morpholin-4-yl-thiazol-4-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidine
  6. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. … Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1).

  7. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. … Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and serine/threonine-protein kinase Chk2.

  8. Drug

    Risvutatug rezetecan

    go.drugbank.com/drugs/DB23560
    Investigational

    It is under investigation in clinical trial NCT06885034 (A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers … Risvutatug rezetecan (GSK5764227) is a novel investigational B7-H3-targeted antibody-drug conjugate.

  9. Drug

    Sulopenem

    go.drugbank.com/drugs/DB15284
    Investigational

    Sulopenem is a penem antibacterial. It is marketed as the prodrug [sulopenem etzadroxil] in combination with [probenecid].[L51768]

  10. Drug

    ZK-93423

    go.drugbank.com/drugs/DB17063
    Experimental

    ZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.[A253172]